{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:48:09Z","timestamp":1762231689871,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["ZL2024H005"],"award-info":[{"award-number":["ZL2024H005"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274028"],"award-info":[{"award-number":["82274028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.dmd.2025.100159","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T23:46:34Z","timestamp":1757375194000},"page":"100159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated plasma levels of the uremic toxin indoxyl sulfate positively correlates with plasma arsenic levels in acute promyelocytic leukemia patients: Evidence of renal AQP7 suppression mediated by the aryl hydrocarbon receptor"],"prefix":"10.1016","volume":"53","author":[{"given":"Shuo","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenli","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Hai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.dmd.2025.100159_bib1","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/cncr.11314","article-title":"Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience","volume":"97","author":"Lazo","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.dmd.2025.100159_bib2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1586\/era.11.128","article-title":"Arsenic trioxide in acute promyelocytic leukemia: potion not poison","volume":"11","author":"Powell","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.dmd.2025.100159_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jpba.2019.04.014","article-title":"Speciation analysis of arsenic in urine samples from APL patients treated with single agent As2O3 by HPLC-HG-AFS","volume":"171","author":"Guo","year":"2019","journal-title":"J Pharm Biomed Anal"},{"issue":"14","key":"10.1016\/j.dmd.2025.100159_bib4","doi-asserted-by":"crossref","first-page":"23905","DOI":"10.18632\/oncotarget.14733","article-title":"Metabolism, toxicity and anticancer activities of arsenic compounds","volume":"8","author":"Khairul","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.dmd.2025.100159_bib5","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/10781552211024727","article-title":"Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia","volume":"28","author":"Zacholski","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"4-5","key":"10.1016\/j.dmd.2025.100159_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2010.04.001","article-title":"Arsenic trioxide - an old drug rediscovered","volume":"24","author":"Emadi","year":"2010","journal-title":"Blood Rev"},{"key":"10.1016\/j.dmd.2025.100159_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.envint.2019.02.058","article-title":"Pathways of arsenic uptake and efflux","volume":"126","author":"Garbinski","year":"2019","journal-title":"Environ Int"},{"issue":"10","key":"10.1016\/j.dmd.2025.100159_bib8","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00204-014-1326-3","article-title":"High accumulation of arsenic in the esophagus of mice after exposure to arsenite","volume":"89","author":"Sumi","year":"2015","journal-title":"Arch Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100159_bib9","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.bbrc.2004.03.003","article-title":"Arsenic trioxide uptake by human and rat aquaglyceroporins","volume":"316","author":"Liu","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.dmd.2025.100159_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1289\/ehp.8600","article-title":"Methylarsonous acid transport by aquaglyceroporins","volume":"114","author":"Liu","year":"2006","journal-title":"Environ Health Perspect"},{"issue":"2","key":"10.1016\/j.dmd.2025.100159_bib11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1021\/tx200491f","article-title":"In vitro study of transporters involved in intestinal absorption of inorganic arsenic","volume":"25","author":"Calatayud","year":"2012","journal-title":"Chem Res Toxicol"},{"issue":"9","key":"10.1016\/j.dmd.2025.100159_bib12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/17512433.2021.1938549","article-title":"Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide","volume":"14","author":"Zhao","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100159_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115299","article-title":"Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia","volume":"409","author":"Wang","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100159_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1021\/tx0341714","article-title":"Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment","volume":"17","author":"Wang","year":"2004","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100159_bib15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00280-009-1169-4","article-title":"A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment","volume":"66","author":"Sweeney","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100159_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018438","article-title":"Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations","volume":"6","author":"Mutsaers","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.dmd.2025.100159_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.semnephrol.2014.02.010","article-title":"The kidney and uremic toxin removal: glomerulus or tubule?","volume":"34","author":"Masereeuw","year":"2014","journal-title":"Semin Nephrol"},{"issue":"1-2","key":"10.1016\/j.dmd.2025.100159_bib18","first-page":"1","article-title":"Uremic toxicity of indoxyl sulfate","volume":"72","author":"Niwa","year":"2010","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.dmd.2025.100159_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100406","article-title":"Inhibitory effects of indoxyl sulfate and creatinine on the renal transport of meropenem and biapenem in rats","volume":"40","author":"Ichimura","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"issue":"9","key":"10.1016\/j.dmd.2025.100159_bib20","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s11095-022-03324-9","article-title":"Mechanistic study on the effect of renal impairment on the pharmacokinetics of vildagliptin and its carboxylic acid metabolite","volume":"39","author":"Guo","year":"2022","journal-title":"Pharm Res"},{"key":"10.1016\/j.dmd.2025.100159_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.116140","article-title":"Advanced oxidation protein products upregulate ABCB1 expression and activity via HDAC2-Foxo3\u03b1-mediated signaling in vitro and in vivo","volume":"449","author":"Xun","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dmd.2025.100159_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lfs.2017.07.027","article-title":"Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease","volume":"185","author":"Gao","year":"2017","journal-title":"Life Sci"},{"issue":"10","key":"10.1016\/j.dmd.2025.100159_bib23","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1080\/10408398.2019.1598334","article-title":"Tryptophan (Trp) modulates gut homeostasis via aryl hydrocarbon receptor (AhR)","volume":"60","author":"Sun","year":"2020","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"3","key":"10.1016\/j.dmd.2025.100159_bib24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1681\/ASN.2017030361","article-title":"Indoxyl sulfate upregulates liver p-glycoprotein expression and activity through aryl hydrocarbon receptor signaling","volume":"29","author":"Santana Machado","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.dmd.2025.100159_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111233","article-title":"Intracellular tacrolimus concentration correlates with impaired renal function through regulation of the IS-AHR-ABC transporter in peripheral blood mononuclear cells","volume":"126","author":"Guo","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100159_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dmd.2025.100159_bib27","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1080\/0886022X.2022.2143378","article-title":"Panax notoginseng saponins alleviate damage to the intestinal barrier and regulate levels of intestinal microbes in a rat model of chronic kidney disease","volume":"44","author":"Xie","year":"2022","journal-title":"Ren Fail"},{"issue":"7","key":"10.1016\/j.dmd.2025.100159_bib28","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s10157-019-01727-4","article-title":"Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats","volume":"23","author":"Sueyoshi","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.dmd.2025.100159_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114858","article-title":"Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients","volume":"163","author":"Lv","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.dmd.2025.100159_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0090-9556(24)13357-0","article-title":"Delayed elimination of SN-38 in cancer patients with severe renal failure","volume":"39","author":"Fujita","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2025.100159_bib31","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41401-021-00781-7","article-title":"Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR\/IL-22 pathway in ILC3s","volume":"43","author":"Li","year":"2022","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"10.1016\/j.dmd.2025.100159_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jcph.444","article-title":"Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease","volume":"55","author":"Tortorici","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100159_bib33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.18433\/J3M89Q","article-title":"Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver","volume":"17","author":"Sato","year":"2014","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"10.1016\/j.dmd.2025.100159_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10534-015-9901-5","article-title":"Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3","volume":"29","author":"\u0160lejkovec","year":"2016","journal-title":"Biometals"},{"issue":"4","key":"10.1016\/j.dmd.2025.100159_bib35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/biomedicines9040426","article-title":"Membrane carriers and transporters in kidney physiology and disease","volume":"9","author":"Drozdzik","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.dmd.2025.100159_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10534-009-9273-9","article-title":"Pentavalent methylated arsenicals are substrates of human AQP9","volume":"23","author":"McDermott","year":"2010","journal-title":"Biometals"},{"issue":"3","key":"10.1016\/j.dmd.2025.100159_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/toxins14030177","article-title":"The interplay between uremic toxins and albumin, membrane transporters and drug interaction","volume":"14","author":"Cunha","year":"2022","journal-title":"Toxins (Basel)"},{"issue":"2","key":"10.1016\/j.dmd.2025.100159_bib39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF03655571","article-title":"Aquaporins","volume":"54","author":"Echevarr\u00eda","year":"1998","journal-title":"J Physiol Biochem"},{"issue":"2","key":"10.1016\/j.dmd.2025.100159_bib40","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/ijms20020366","article-title":"Aquaporins in renal diseases","volume":"20","author":"He","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.dmd.2025.100159_bib41","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbamem.2006.04.002","article-title":"Physiological roles of AQP7 in the kidney: lessons from AQP7 knockout mice","volume":"1758","author":"Sohara","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.dmd.2025.100159_bib42","article-title":"AhR activation during chronic renal failure is not associated with infectious risk but with the number of neutrophils. Article in French","volume":"12","author":"Megan","year":"2016","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.dmd.2025.100159_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152841","article-title":"Bioavailability of the diterpenoid 14-deoxy-11,12-didehydroandrographolide in rats and up-regulation of hepatic drug-metabolizing enzyme and drug transporter expression","volume":"61","author":"Yen","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.dmd.2025.100159_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.620197","article-title":"Transporter gene regulation in sandwich cultured human hepatocytes through the activation of constitutive androstane receptor (CAR) or aryl hydrocarbon receptor (AhR)","volume":"11","author":"Niu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100159_bib45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.abb.2007.08.007","article-title":"Curcumin suppresses the transformation of an aryl hydrocarbon receptor through its phosphorylation","volume":"466","author":"Nishiumi","year":"2007","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"10.1016\/j.dmd.2025.100159_bib46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/jat.916","article-title":"Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene","volume":"23","author":"Revel","year":"2003","journal-title":"J Appl Toxicol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:43:54Z","timestamp":1762231434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0090955625091688"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100159","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated plasma levels of the uremic toxin indoxyl sulfate positively correlates with plasma arsenic levels in acute promyelocytic leukemia patients: Evidence of renal AQP7 suppression mediated by the aryl hydrocarbon receptor","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100159"}}